Ipsen’s Dysport Likely Impacted By COVID-19 In Q2, But China Sales To Return
Specialty Portfolio Drives Ipsen In First Quarter
Sales grew 9.6% at Ipsen in the first quarter, and the search for a new CEO is on track, but France’s specialty pharmaceutical company maintained its 2020 guidance suspension because of the uncertainty over the course of the COVID-19 pandemic.
You may also be interested in...
The new Ferring-backed gene therapy company has bagged a big name player in David Meek as its CEO but the move has created a void at the top for France's Ipsen.
Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.